Copy number variants landscape of multiple cancers and clinical applications based on NGS gene panel
Authors:
Open Access
- 15 November 2023
- journal article
- research article
- Published by Taylor & Francis in Annals of Medicine
- Vol. 55 (2) , 2280708
Abstract
The rapid adoption of next-generation sequencing in clinical oncology has enabled detection of molecular biomarkers which are shared between multiple tumour types. Intra-tumour heterogeneity is a mechanism of therapeutic resistance and therefore an important clinical challenge. However, the tumour-related copy number variants (CNVs), as key regulators of cancer origination, development, and progression, across various types of cancers are poorly understood. We performed pan-cancer CNV analysis of cancer-related genes in 15 types of cancers including 1438 cancerous patients by next-generation sequencing using a commercially available pan-cancer panel (Onco PanScan™). Downstream bioinformatics analysis was performed in order to detect CNVs, cluster analysis of the found CNVs, and comparison of the frequency of gained CNVs between different types of cancers. LASSO analysis was used for identification of the most important CNVs. We also identified 523 CNVs among which 16 CNVs were common while 22 CNVs were caner-specific CNVs. Meanwhile, FAM58A was most commonly found in all studied cancers in this study and significant differences were found in FAM58A between female and male patients (p = .001). Common CNVs, such as FOXA1, NFKBIA, HEY1, MECOM, CHD7, AGO2, were mutated in 6.79%, 8.45%, 7.51%, 6.43%, 7.59%, 8.16% of tumours, while most of these mutations have proven roles in positive regulation of transcription from RNA polymerase II promoter. 11 features including sex, DIS3, EPHB1, ERBB2, FLT1, HCK, KEAP1, MYD88, PARP3, TBX3, and TOP2A were found as the key features for classification of cancers using CNVs. The 16 common CNVs between cancers can be used to identify the target of pan-cancer drug design and targeted therapies. Additionally, 22 caner-specific CNVs can be used as unique diagnostic markers for each cancer type.Keywords
This publication has 30 references indexed in Scilit:
- Suberoylanilide hydroxamic acid (SAHA) promotes the epithelial mesenchymal transition of triple negative breast cancer cells via HDAC8/FOXA1 signalsBiological Chemistry, 2016
- Decreased CDK10 expression correlates with lymph node metastasis and predicts poor outcome in breast cancer patients - a short reportCellular Oncology, 2015
- Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancerNature Genetics, 2014
- Credit for codeNature Genetics, 2013
- Integrative genomics analysis reveals the multilevel dysregulation and oncogenic characteristics of TEAD4 in gastric cancerCarcinogenesis, 2013
- Clinical and biological significance of Cdk10 in hepatocellular carcinomaGene, 2012
- CDK10 functions as a tumor suppressor gene and regulates survivability of biliary tract cancer cellsOncology Reports, 2011
- Proyl isomerase Pin1 facilitates ubiquitin-mediated degradation of cyclin-dependent kinase 10 to induce tamoxifen resistance in breast cancer cellsOncogene, 2011
- Epigenetic modifications in cancerClinical Genetics, 2011
- Copy-number variation: the end of the human genome?Trends in Biotechnology, 2009